Australian Clinical Labs Ltd (AU:ACL) has released an update.
Australian Clinical Labs Ltd witnessed a significant shift in its shareholding structure as Crescent Capital Partners, ROC Capital, and Instanz Nominees offloaded a substantial number of shares through a Block Trade Agreement dated 12 September 2024. Each share was sold at $3.20, affecting tens of millions of ordinary shares and altering the voting power within the company. This move marks a change in the investment landscape of the company, reflecting adjustments in strategic holdings by key financial entities.
For further insights into AU:ACL stock, check out TipRanks’ Stock Analysis page.
